Replimune Group, Inc. announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company's upcoming annual general meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 USD | -7.76% | -9.86% | -29.54% |
May. 16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.54% | 396M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors